The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present report, we describe an adult male patient with clomipramine treatmentYresistant OCD who did not respond to augmentation with risperidone and aripiprazole but who showed clinical improvement with agomelatine. The effect of agomelatine in resynchronizing circadian rhythms may demonstrate the importance of the circadian rhythm disruption observed in OCD. Moreover, the regulation of the serotoninergic system is circadian in nature, and the resynchronization of the serotoninergic system may regulate serotoninergic dysfunction, a major factor in OCD.
S erotonin reuptake inhibitors (SRIs) are well-established pharmacotherapy agents for the treatment of obsessive-compulsive disorder (OCD). However, approximately 60% of OCD patients do not respond adequately to SRI therapy. 1Y4 The main type of augmentation strategy is the addition of low-dose dopamine antagonists, such as risperidone. This type of augmentation works relatively quickly (in approximately 1 month). 4 However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to this strategy. 1 In the present report, we describe an adult male patient with clomipramine treatmentYresistant OCD who did not respond to augmentation with risperidone and aripiprazole but who showed clinical improvement with agomelatine.
CASE REPORT
A 17-year-old black male patient was admitted to our department with a 3-year history of OCD. A previous history of psychiatric treatment (1 year prior) with sertraline (200 mg daily) for 7 months did not improve his symptoms.
The patient's obsessions were related to the contamination of his body after returning from public places. His compulsions were characterized by cleaning and washing rituals.
When returning home, he washed each part of his body exactly 72 times (''the good number'') in a specific order. Even when the patient did not leave his home, he washed his hands unnecessarily more than 5 times a day (72 times each time), causing severe skin injuries. He was aware that these behaviors were excessive, and they caused marked distress in his life. He scored 36 (16 for obsessions and 20 for compulsions) on the Yale-Brown Obsessive-Compulsive Scale (YBOCS). On the Beck Depression Inventory II (BDI), he scored 25, indicating moderate depression. His score on the Yale Global Tic Severity Scale was 2, indicating the presence of 1 simple motor tic characterized by rare episodes with no significant impact on his life.
Laboratory results, including complete blood count; creatine kinase level; electrolytes; and renal, liver, and thyroid function tests, were unremarkable.
The patient was adequately treated with clomipramine (225 mg daily) for a period of 5 months with no clinical improvement (discrete decrease of his YBOCS score to 34), although his BDI score decreased to 19.
Augmentation with risperidone (2 mg daily) for 6 months, and subsequently with aripiprazole (10 mg daily) for 35 days, did not improve his disorder, as reflected by high YBOCS scores and a lack of change in his BDI score (18 points at this time).
Agomelatine (25 mg daily) was added to his treatment, and it led to a significant improvement in the patient's depressive symptoms for the following 2 weeks (BDI score decreased to 8). The YBOCS score improved as well, decreasing to 11 after 3 more weeks, with a robust clinical improvement observed for the patient. At the last follow-up visit 3 months later, the improvement was sustained.
DISCUSSION
Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and a 5-HT2C antagonist. Binding studies indicate that it has no effect on monoamine uptake. 5 However, recent data support the notion that the recoordination of biological rhythms through melatonergic mechanisms is a therapeutically relevant strategy for improving depressed states. These data are consistent with evidence illustrating that the intensity of symptoms in individuals with major depression is correlated with circadian misalignment. 5, 6 A major goal of in vivo studies of agomelatine was to demonstrate its efficacy in normalizing disturbances of circadian rhythms, especially in models related to depressed states. In humans, agomelatine has positive phase-shifting properties; it induces an advance in the sleep phase, a body temperature decline, and the release of melatonin. 5 The observation that agomelatine blocked 5-HT2C receptors was of considerable interest because these receptors fulfill major roles in the control of mood and in the response to stress. Furthermore, serotonin synthesis is highly circadian. The suprachiasmatic nucleus (SCN) is intensely innervated by serotonergic pathways emanating from the raphe nucleus, and SCN-localized 5-HT2C receptors contribute to the integration of photic and nonphotic modulation of circadian rhythms. Nevertheless, actions of melatonergic and 5-HT2C receptors colocalized in the SCN may participate in the SCN's influence on circadian rhythms and in its resynchronizing actions. 5, 6 Biomarkers of circadian rhythm disruption have been studied intensively in psychiatric disorders, with studies demonstrating several promising findings. 6 Individuals with OCD show hypervigilance and problems falling asleep. 7Y9 Biomarkers of circadian rhythms have been found in patients with OCD. The OCD patients demonstrate hyperactivity of the hypothalamicpituitary-adrenal axis and have increased secretion of adrenocorticotropic hormone and cortisol and a reduced secretion of melatonin. 7Y10 Although the importance of the circadian patterns of the plasma levels of melatonin and cortisol are noted, studies with SRIs demonstrate that the normalization of the biochemical changes underlying the altered endocrine parameters is not necessary for effective therapy or clinical remission. 11, 12 Several hypotheses may explain the significant improvement observed in this case. Agomelatine's effect on resynchronizing circadian rhythms may demonstrate the importance of circadian rhythm disruption observed in OCD. Another important factor is the relationship between circadian rhythms and the serotoninergic system. 5, 6 Because the regulation of the serotoninergic system is circadian in nature, resynchronization of the serotoninergic system may regulate serotoninergic dysfunction, a major factor in OCD. However, it is not known whether such alterations play an etiological role or whether they are secondary to the dysfunctions underlying OCD.
In conclusion, further research is necessary to determine whether agomelatine is an effective augmentation strategy for treatment-refractory OCD and to determine which types of OCD patients are most responsive to this type of therapy. Novel treatment interventions must be developed for the roughly two thirds of treatment-refractory OCD patients who do not respond to antipsychotic augmentation, the most studied strategy for these patients. 4 
